AXGNHealthcare · Medical DevicesThe 12 Wall Street analysts covering Axogen, Inc. hold a median 12-month price target of $54 — +53.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Axogen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (93): The shares have been drifting up relative to others.
Growth (51): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (34): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AXGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +53.7% from it.
Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | B of A Securities | Initiates | Buy | $52 |
| 7 Oct 2026 | Barclays | Initiates | Overweight | $55 |
| 1 Oct 2026 | Truist Securities | Maintains | Buy | $60 → $53 |
| 25 Sept 2026 | Raymond James | Maintains | Outperform | — |
| 25 Sept 2026 | Raymond James | Maintains | Outperform | $48 → $53 |
| 26 Aug 2026 | Truist Securities | Initiates | Buy | $60 |
| 26 Aug 2026 | Truist Securities | Initiates | Buy | — |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | $50 → $55 |
| 30 July 2026 | Citizens | Maintains | Market Outperform | $50 → $55 |
| 30 July 2026 | Citizens | Maintains | Market Outperform | — |
| 30 July 2026 | HC Wainwright & Co. | Maintains | Buy | $50 → $53 |
| 30 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Apr 2026 | Canaccord Genuity | Maintains | Buy | $45 → $50 |
| 29 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 29 Apr 2026 | Citizens | Maintains | Market Outperform | $42 → $50 |
| 29 Apr 2026 | Citizens | Maintains | Market Outperform | — |
| 29 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | $39 → $50 |
| 29 Apr 2026 | Wells Fargo | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AXGN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Axogen, Inc. returned +121.4% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 16% of US stocks
Cheaper than 12% of US stocks
Cheaper than 98% of US stocks
Higher than 72% of US stocks
Higher than 61% of US stocks
Higher than 85% of US stocks
Higher than 29% of US stocks
Higher than 18% of US stocks
Higher than 32% of US stocks
Higher than 35% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Axogen, Inc. has a market value of $2.1B and an enterprise value of $1.9B.
Revenue in the twelve months to 30 June 2026: $251.2M. The latest quarter grew 23.1% year on year.
Net income over the same four quarters: −$33.5M, a −13.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.68.
Free cash flow in the twelve months to 30 June 2026: $6.5M.
Trailing P/E: −106.4×; forward P/E: 50.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Axogen, Inc. employs 622 people — $404K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Axogen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Axogen, Inc. announced that it will report third-quarter 2026 financial results on October 28, 2026.
Why it matters — AXGN watchers may note the date when the company plans to release its quarterly financial results.
AxoGen (AXGN) has declined 22.6% over the past four weeks and is now technically in oversold territory. According to the report, strong agreement among Wall Street analysts in revising earnings estimates higher indicates the stock may be poised for a trend reversal.
Why it matters — For AxoGen watchers, this report suggests that the recent selloff may have run its course, with analyst estimate revisions pointing to a possible turnaround in the stock's direction.
Axogen announced the completion of its acquisition of BioCircuit Technologies, adding NerveTape, the first FDA-cleared device for sutureless peripheral nerve repair, to its portfolio. The announcement was made from Alachua, Florida and Tampa, Florida.
Why it matters — This acquisition expands Axogen's product offerings with a novel FDA-cleared sutureless nerve repair device, potentially broadening its addressable market in peripheral nerve repair.
Axogen Inc. agreed on Thursday to acquire privately held BioCircuit Technologies Inc., a medical device manufacturer, for $200 million in cash. The acquisition is focused on BioCircuit's sutureless nerve repair technology.
Why it matters — The acquisition expands Axogen's portfolio in nerve repair by adding BioCircuit's sutureless technology, which could affect the company's product offerings and competitive position.
Schaeffers Research reports that Axogen Inc, alongside Cooper Companies, is sharply lower after separate company developments, with options traders responding to the moves.
Why it matters — Axogen watchers would note the sharp decline in the stock following a company development, as it reflects heightened options-market activity around the news.
The 12 Wall Street analysts covering Axogen, Inc. have a median 12-month price target of $54, with estimates ranging from $48 to $58. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Axogen, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Axogen, Inc. 80 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Axogen, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +53.7% from the last close, and Ticker Nerd's factor model ranks Axogen, Inc. 80 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Axogen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AXGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $48 to $58 over the next 12 months.
Axogen, Inc. returned +121.4% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Axogen, Inc. is a medical technology company focused on peripheral nerve regeneration and repair.
The most recent item we track (GlobeNewsWire, 14 Oct 2026): "Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026". Axogen, Inc. announced that it will report third-quarter 2026 financial results on October 28, 2026.
Axogen, Inc. is a medical technology company focused on peripheral nerve regeneration and repair. Axogen develops and commercializes surgical solutions used by surgeons and healthcare providers to address nerve injuries caused by trauma, procedures, or disease. Its current product portfolio includes nerve allografts, nerve connectors, nerve protectors, nerve caps, and soft tissue membranes designed to support nerve reconstruction, protection, and functional restoration. The company serves hospitals, surgery centers, military hospitals, and specialists in reconstructive, hand, orthopedic, plastic, and oral and maxillofacial surgery. Axogen plays a specialized role in the medical devices market by offering targeted technologies for peripheral nerve care and by supporting clinical education around surgical treatment of nerve damage. Headquartered in Alachua, Florida, Axogen remains focused on a niche segment of regenerative medicine and surgical reconstruction.
CEO Mr. Michael D. Dale · 622 employees · United States · https://www.axogeninc.com
